- Sonova announces that Cameron Hay is standing down as president and CEO of Unitron Hearing
Cameron Hay is leaving Sonova Holding AG after over five years as a member of the Management Board to take on new professional and personal challenges outside the Group. Sonova Holding AG will appoint his successor shortly.
- Neuro-Ophthalmologist joins diopsys as research director
Dr. Alberto Gonzalez Garcia has joined Diopsys, Inc. as its new Research Director. Dr. Gonzalez will head all scientific research for new product development and enhancement projects, including clinical studies.
- Merck taps Kenneth Frazier as CEO
Merck & Co. (NYSE:MRK) picked a lawyer for its new CEO, becoming the latest pharmaceutical maker to name a leader from outside of the laboratory as issues like defending patents and controlling costs have become greater, according to The Wall Street Journal.
- Light Sciences Oncology chief executive out
Llew Keltner leaves his CEO post at Light Sciences Oncology to become CEO of another biotech, according to Xconomy Seattle.
- Martin Madaus joins Quanterix board of directors
Quanterix Corp. announced hat Martin Madaus joined the company’s board as executive chairman. Madaus brings more than 20 years of experience in the diagnostics and life science industries, most recently serving as president, chairman and CEO of Millipore Corp., recently acquired by Merck KGaA.
- CareFusion names James Hinrichs CFO
CareFusion Corp. (NYSE:CFN), a leading, global medical device company, announced that James Hinrichs has been promoted to CFO, replacing Edward Borkowski who will leave the company at the end of the month.
- Alquest hires veteran heart valve and pacing executive
Medical Device CRO Alquest hired Vickie Conley, a top market and product development executive specialized in heart valve therapies and cardiac rhythm management.
- VisionCare appoints Richard Powers executive vice president
VisionCare Ophthalmic Technologies Inc., a developer of advanced visual prosthetic devices, today announced Richard P. Powers has been appointed Executive Vice President. Mr. Powers joins the company as it expands management capabilities and adds resources during the company’s commercialization of its products designed to improve vision in patients with end-stage age-related macular degeneration.
- Hill-Rom appoints Brian Lawrence as CTO
Hill-Rom (NYSE:HRC) announced the appointment of Brian Lawrence as senior vice president and CTO. He will join Hill-Rom on Dec. 6.
- Covance announces key executive promotions and appointment
Covance Inc. (NYSE:CVD), a leading provider of drug development services, announces the promotions of Rick Cimino to executive vice president and group president, clinical development; Deborah Tanner to executive VP and group president, R&D laboratories; and John Watson to corporate senior VP, president, strategic partnering, and chief commercial officer. In addition, Jon Koch was promoted to corporate VP and president, central laboratory services and Lisa Uthgenannt joined Covance as corporate VP of human resources.
- Orthofix International announces resignation of Thomas Kester from board of directors
Orthofix International N.V. (NSDQ:OFIX) announced that Thomas Kester has resigned, effective immediately, from the company’s board of directors. Mr. Kester has been an independent director of Orthofix since August of 2004. He served as a member of the audit committee and chairman of the compensation committee. His resignation is not because of a disagreement with the company on any matter relating to the company’s operations, policies or practices.
- Surgeon Anthony Senagore joins AeroSurgical
Dr. Anthony Senagore, a highly regarded surgeon who is currently chief of colon and rectal surgery at the University of Southern California-Keck School of Medicine, has agreed to become the chief medical officer for AeroSurgical Limited, a medical device company. AeroSurgical is developing products to improve clinical outcomes through the use of its proprietary, state-of-the-art aerosol platform to deliver therapeutics to patients during laparoscopic surgery.
- NeurogesX appoints new director to board
NeurogesX Inc. (NSDQ:NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced that the board of directors has voted to expand the size of the company’s board from six to seven members with the appointment of Steven Nelson, effective Nov. 17.